In the present study, the expression of L1 cell adhesion molecule (L1-CAM) and the serum levels of its soluble form, sL1, were analyzed in 162 primary breast cancer (PBC) patients. Overexpression of L1-CAM in cancer tissues and higher levels of sL1 were associated with worse clinicopathologic characteristics and a poor prognosis. L1-CAM and sL1 might be useful as a biomarker and target for PBC. Introduction: The L1 cell adhesion molecule (L1-CAM) and its soluble form sL1 play a prominent role in invasion and metastasis in several cancers. However, its association with breast cancer is still unclear. Patients and Methods: We analyzed L1-CAM expression and serum sL1 levels in cancer and para-carcinoma tissues from 162 consecutive patients with primary invasive breast cancer (PBC) using immunohistochemistry and an enzyme-linked immunosorbent assay, respectively. The serum sL1 levels were also examined in 38 patients with benign breast disease and 36 healthy controls. Results: L1-CAM was expressed more frequently in cancer tissues than in para-carcinoma tissues (24.1% vs. 5.6%; P < .001), and the mean sL1 levels were significantly greater in PBC than in those with benign breast disease and healthy controls (P ¼ .027). Both L1-CAM þ expression and higher mean sL1 levels correlated significantly with larger tumor size, lymph node involvement, higher histologic grade, advanced TNM stage, and shorter diseasefree survival for PBC patients. Moreover, higher mean sL1 levels were also significantly associated with estrogen receptor-aenegative expression, human epidermal growth factor receptor 2-positive (HER2 þ ) expression, HER2-enriched and triple-negative molecular subtypes, and L1-CAM þ expression (P < .05). On multivariate analysis, larger tumor size, nodal involvement, HER2 þ , and higher sL1 levels (! 0.7 ng/mL) were independent factors associated with L1-CAM þ expression (P < .05). No association was found between L1-CAM expression or sL1 level with age, gender, histologic type, or expression of progesterone receptor, Ki-67, p53, or vascular endothelial growth factor C (P > .05). Conclusion: These results indicate that L1-CAM and sL1 are elevated in PBC and both might affect the prognosis of PBC patients. In addition, sL1 might be a useful marker for screening and diagnosis.
Introduction
The L1 cell adhesion molecule (L1-CAM; CD171) was originally discovered as an important protein that plays a crucial role in axon guidance and cell migration in the nervous system. [1] [2] [3] Recently, L1-CAM expression was found in many malignant tumors, and this expression correlated with unfavorable clinical outcomes. [4] [5] [6] [7] [8] L1-CAM was reported in some studies to be present at a low percentage (15%-28%) of breast cancers (BCs). 8, 9 In contrast, another study reported that 89% of patients with primary BC in Chinese cohorts expressed high levels of L1-CAM. 10 In addition, overexpression of L1-CAM in BC was associated with cancer progression and poor prognosis.
Soluble L1 (sL1) is the extracellular domain of L1-CAM, which is shed from the cell surface of tumor cells by metalloproteinasemediated cleavage. [11] [12] [13] In ovarian, endometrial, and lung cancer, sL1 is cleaved in the exosomes, which are released continuously from cells and can be found in serum and ascites fluid. 11, 14, 15 Recent studies have shown that sL1 promoted cancer cell migration, invasion, and growth of human cancer cells. 4, 14, 16 However, few studies have addressed L1-CAM expression and its association with clinicopathologic characteristics or the role of serum sL1 in the diagnosis of BC. Furthermore, the association of sL1 with clinicopathologic characteristics remains unknown, and, to the best of our knowledge, its effect on the prognosis of patients has not been investigated. In the present study, we investigated L1-CAM expression and serum sL1 levels with a focus on their potential prognostic value in primary invasive BC (PBC) patients.
Patients and Methods

Patients
The present study enrolled a consecutive series of 162 patients with PBC without distant metastasis, who had not received previous anticancer treatment. The present study also included 38 patients with benign breast disease (BBD) and 36 healthy controls (HCs). The PBC and BBD patients were from the Breast Center and the HCs were recruited from healthy volunteers at the checkup center. All the study participants were enrolled at the Cancer Hospital of Shantou University Medical College from November 2009 to April 2012. The ethics committee of the Cancer Hospital of Shantou University Medical College approved the study, which was performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and all subsequent revisions. All patients and control individuals gave informed consent before inclusion in the present study.
The inclusion criteria were female gender and clinical TNM stage T1-T4N0-N3 according to the AJCC Cancer Staging Manual, seventh edition. 17 All PBC and BBD patients underwent core needle biopsy or resection with histologic confirmation of the diagnosis. Patients with a history of any other malignancy were excluded from the present study. Of the 38 patients with BBD, 14 had fibroadenoma, 9 had intraductal papilloma, 7 had usual ductal hyperplasia, 5 had cysts, 2 had granulomatous lobular mastitis, and 1 had hamartoma. The HCs presented with negative breast findings indicating the absence of BC and had no history of other cancer. The PBC patients were excluded if they met 1 of the following criteria: in situ BC, stage IV BC, critical information unavailable, or no follow-up data available. All the patients (PBC and BBD) underwent physical and imaging examinations and hematologic and biochemical assessments and received appropriate treatment of their primary disease, including surgery or new adjuvant chemotherapy in accordance with the National Comprehensive Cancer Network guidelines. All PBC patients underwent surgery, including breast-conserving surgery or mastectomy with or without breast reconstruction. Systemic therapy was administered in accordance with the clinicopathologic features and molecular subtypes. We analyzed the following variables: age at diagnosis, menopausal status, tumor size, histologic type, histologic grade, estrogen receptor-a (ERa), progesterone receptor (PR), nodal status, human epidermal growth factor receptor 2 (HER2), Ki-67, p53, vascular endothelial growth factor C (VEGF-C), and molecular subtype. Tumor tissues were obtained from paraffin-embedded specimens for hematoxylin and eosin staining, immunohistochemistry (IHC), and fluorescence in situ hybridization staining. Expression of ERa, PR, p53, and VEGF-C was considered positive if immunostaining was positive in ! 10% of tumor cells. 18, 19 HER2 positivity was defined as a score of ! 3 on IHC 18 or amplification by fluorescence in situ hybridization. 20 Ki-67 expression was considered positive if nuclear staining of tumor cells was > 14% and negative if 14%. 21 
Serum sL1 Assays
Fasting peripheral venous blood samples were collected from the 3 groups in 4-mL glass tubes without additive in the morning. The blood samples from the PBC and BBD patients were obtained at diagnosis and before surgery or neoadjuvant chemotherapy. The blood samples were centrifuged at 1600g for 10 minutes at room temperature. The serum was separated into aliquots in microcentrifuge tubes and stored at À80 C for further experimentation.
sL1 was measured using enzyme-linked immunosorbent assay (USCN Life Science Inc, Wuhan, China) according to the manufacturer's instructions. The minimum detectable dose of sL1 was 0.042 ng/mL, and the detection range was 0.094 to 6.000 ng/mL. The samples were measured in duplicate. The intra-and interassay variations were < 20%. For the enzyme-linked immunosorbent assay, all reagents, standard dilutions, and samples were prepared according to the manufacturer's instructions. The standard (range of concentrations), blank, or sample (100 mL) was added to each well.
The plates were covered with a plate sealer and incubated at 37 C for 2 hours. After aspiration, 100 mL of detection reagent A was added to each well, and the plates were resealed and incubated at 37 C for 1 hour. Each well was aspirated, washed 3 times with wash buffer, and 100 mL of detection reagent B was added to each well.
The plates were resealed and incubated for 30 minutes at 37 C.
After aspiration, each well was washed 5 times, 90 mL of substrate solution was added to each well, and the resealed plates were incubated in the dark for 20 minutes at 37 C. The reaction was terminated by the addition of 50 mL of stop solution, and the absorbance was read at 450 nm using a spectrophotometer (MK3; Thermo Fisher Scientific). The concentration of sL1 in the sample was calculated by comparing the obtained absorbance with the relative absorbance of the calibrated standard antigens.
IHC Analysis
The cancer and para-carcinoma samples were obtained by surgical resection if the patient's initial treatment had been surgery. The cancer samples were obtained from the biopsy specimens and paracarcinoma tissue was obtained by surgical resection if the patient's initial treatment had been neoadjuvant chemotherapy. IHC for L1-CAM was performed using a standard EnVision complex method. 22 In brief, 4-mm sections were fixed in 10% buffered formalin and embedded in paraffin. After deparaffinization and rehydration, endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 10 minutes. L1-CAM and sL1 and PBC Prognosis 
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was performed using the GTVision antibody complex (anti-mouse/ rabbit) method and the GTvision I Detection System kit (Gene Tech Co, Ltd, Shanghai, China) with 3,3 0 -diaminobenzidine as the chromogen substrate. The negative control was obtained by replacing the primary antibody with normal rabbit IgG.
Tissue Classification
L1-CAM expressed on the cell membrane and partially in the cytoplasm was considered a positive finding (see Figure 2B ). The frequency and staining intensity of L1-CAM in tumor cells were analyzed independently and blindly by 2 pathologists, who had no knowledge of the patients' identity or clinical outcomes. L1-CAM expression was quantified using a modified histoscore. 23 Using the staining intensity and number of positive cells in the tumor slice, a final immunoreactivity score was obtained for each sample using 2-score multiplication. The score was a point value between 0 and 300. 24 Samples with an immunoreactivity score < 30 were considered negative and those with a score of ! 30 were considered positive.
Follow-up and Study Endpoints
The patients were followed up at 3-to 6-month interval, with the day of the pathologic diagnosis considered the first follow-up day. Patient follow-up data were gathered in the outpatient department, by telephone consultation, or by mailed letters. During the followup period, patient surveillance included physical examination, laboratory tests, chest radiography, and breast and abdominopelvic ultrasonography. Locoregional recurrence was defined as pathologically confirmed relapse on the chest wall, supra-and infraclavicular fossa, axillary area, and/or internal mammary region. Distant metastasis was confirmed using medical imaging and pathologic assessment, as needed. Disease-free survival (DFS) was defined as the period from surgery to locoregional recurrence or distant metastasis. Overall survival (OS) was defined as the interval diagnosis until death.
Statistical Analysis
Statistical analysis was performed using SPSS, version 16.0 software (IBM, Armonk, NY). The serum sL1 levels are reported as the mean AE standard deviation and median. Statistically significant differences in the sL1 levels were determined using the MannWhitney U and Kruskal-Wallis H tests. The association between L1-CAM expression and clinicopathologic variables was assessed using the c 2 or Fisher exact test. Univariate analysis was performed to assess the risk factors for L1-CAM þ expression. Variables with P < .05 on multivariate analysis were included in a binary logistic regression analysis using a backward selection procedure to discover the independent risk factors for L1-CAM þ expression. Receiver operating characteristic (ROC) curves were drawn, and the area under the curve (AUC) was used to assess the predictive accuracy of sL1 levels between PBC patients and HCs plus those with BBD. DFS and OS were plotted using the Kaplan-Meier method and analyzed using the log-rank test. For all analyses, P < .05 was considered to indicate statistical significance.
Results
Characteristics of PBC, BBD, and HC Samples
The present study included 162 consecutive patients with PBC, 38 patients with BBD, and 36 HCs. The median age of the PBC patients, BBD patients, and HCs was 61 years (range, 28-81 years), 53 years (range, 18-68 years), and 47 years (range, 30-70 years), respectively. The characteristics and clinicopathologic data for the PBC patients are listed in Table 1 .
Serum sL1 Levels and Prognostic Value in PBC
The median, 25th and 75th percentiles, and mean serum sL1 levels were 0.55, 0.36 and 0.82, and 0.76 AE 0.70 ng/mL for PBC, 0.59, 0.18 and 0.75, and 0.51 AE 0.29 ng/mL for BBD, and 0.45, 0.17 and 0.75, and 0.47 AE 0.29 ng/mL for HC patients, respectively ( Table 2) . The serum sL1 levels in the PBC patients were significantly greater than those in the BBD and HC groups (P ¼ .027). No statistically significant difference was found in the serum sLI levels between the BBD and HC groups (P ¼ .611; Figure 1A) .
To evaluate the diagnostic value of the serum sL1 levels, we used ROC methods to calculate the sensitivity and specificity of sL1. The AUC between the patients with PBC and the HCs plus those with BBD was 0.61 (95% confidence interval, 0.52-0.69; P ¼ .009), indicating that sL1 had significant predictive accuracy in PBC patients ( Figure 1B) .
Association of L1-CAM Expression and Clinical PBC Outcomes
L1-CAM expression was detected on the membrane and with cytoplasmic staining of the cancer cells by IHC. Of the 162 PBC patients, 39 had L1-CAM þ expression (24.1%; Figure 2B ). Only 9 of the 162 para-carcinoma samples expressed L1-CAM (5.6%), with a significantly greater number of L1-CAM þ samples among the cancer tissues compared with the para-carcinoma tissues (P < .001; Table 1 ). L1-CAM expression was also found in vascular endothelial cells and , and higher sL1 levels (! 0.7 ng/mL) were identified as independent factors associated with L1-CAM þ expression in PBC patients (Table 3) .
Association of sL1 Levels and Clinicopathologic Characteristics in PBC Patients
Our data indicated that L1-CAM þ patients had higher serum sL1 levels compared with those with L1-CAM À expression (P < .001; Table 2 ). Moreover, higher mean sL1 levels were significantly associated with larger tumor size, positive lymph nodes, higher grade, more advanced TNM stage, negative ERa expression, positive HER2 expression, and HER2-enriched and triple-negative subtypes. No association was observed between the different groups and patient age, menopausal status, histological type, or expression of PR, Ki-67, p53, or VEGF-C (Table 2) .
Follow-up and Survival Analysis
All the patients in our study were followed up with a median followup time of 71 months (range, 8-82 months). The DFS was significantly shorter for the LI-CAM þ patients compared with that of the LI-CAM À patients (P ¼ .02; Figure 3A ). No significant difference was found in OS between the LI-CAM þ and LI-CAM À patients (P ¼ .13; Figure 3B ). For additional statistical analysis, patients with high (! 0.70 ng/mL) and low (< 0.70 ng/mL) sL1 levels were compared by survival curves plotted using the Kaplan-Meier method for DFS and OS. The DFS was significantly shorter for the higher sL1 level group compared with that for the lower sL1 level group (P ¼ .02; Figure 3C ). No significant difference in OS was found between these 2 groups (P ¼ .064; Figure 3D ).
Discussion
Previous reports have demonstrated conflicting data for the expression of L1-CAM in BC. Huszar et al 25 demonstrated that L1-CAM was always negative in cases of infiltrating ductal carcinoma of the breast using IHC. However, other studies have shown L1-CAM þ expression in BC tissues. [8] [9] [10] 26 Of special interest was the expression of L1-CAM in many breast carcinoma cell lines in vitro. 25 In our study, we investigated the expression of L1-CAM in 162 specimens from PBC patients with IHC using the monoclonal rabbit antibody and found L1-CAM expressed in 24.1% of the PBC specimens. The expression rate was consistent with those from previous reports. 8, 9, 26 The conflicting data on L1-CAM expression in BC using IHC might have resulted from differences in antibody type, localization of L1-CAM expression, and use of the immunoreactivity score. In their study, Huszar et al 25 used
the mouse monoclonal antibodies L1-14.10, which do not have the best sensitivity. Inaguma et al 26 compared 3 different CD171 antibodies in normal and selected tumor tissues in their study. They found that mouse monoclonal antibodies L1-14.10 and UJ127.11 showed higher background signals in the smooth muscle layer of the gastrointestinal tract and thyroid glands. 26 In contrast, rabbit monoclonal antibody had the best sensitivity and lacked the background signal generated by the L1-14.10 and UJ127.11 antibodies. Also, rabbit monoclonal antibody offered excellent signal quality with almost no background signals in normal tissues. 26 Localization of L1-CAM expression and the use of the immunoreactivity score are additional factors. The specimens were considered to have L1-CAM þ expression only when > 10% of tumor cells had strong membranous staining in the study by Huszar et al. 25 That requirement would reduce the rate of positivity. However, in our study, and other studies, L1-CAM expression in the tumor cell membrane and cytoplasmic were considered to indicate positive expression. The positive rate was 15% to 28.8%. 8, 9, 26 In another study, the L1-CAM þ expression rate was as high as 89%. 10 The primary antibody for L1-CAM (a goat polyclonal L1-CAM antibody; sc-31032) used in that study might have affected the specificity. We also found cytoplasmic staining and greater background signals in their data. In our study, in contrast, only 5.6% of the corresponding para-carcinoma tissue expressed L1-CAM, and L1-CAM expression was found predominantly in cancerous tissues and rarely in normal tissues, suggesting it is a potential marker for tumorigenesis and progression. 27 Our results further showed that L1-CAM þ expression was associated with larger tumor size, nodal involvement, higher histologic grade, more advanced TNM stage, and higher sL1 levels on univariate analysis. Moreover, larger tumor size, nodal involvement, HER2 þ expression, and higher sL1 levels (! 0.7 ng/mL) were identified as 
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Clinical Breast Cancer October 2018 -e857 independent factors associated with L1-CAM þ expression on multivariate analysis, consistent with previous studies. 4, [8] [9] [10] These findings have confirmed that L1-CAM expression occurs mainly at the invasive front of BC tissues and in the vascular endothelial cells ( Figure 2C,D) , suggesting a role for L1-CAM in the malignant progression and aggressiveness of cancer. 4, [8] [9] [10] [27] [28] [29] In addition, L1-CAM þ patients had poorer DFS compared with L1-CAM À negative patients.
These data are consistent with the association between L1-CAM overexpression and poor prognosis in other malignancies (eg, colorectal cancer, uterine cancer, ovarian cancer, melanoma, clear cell renal carcinoma, non-small cell lung cancer, and pancreatic ductal adenocarcinoma). 28, [30] [31] [32] [33] Furthermore, because L1-CAM localizes to the cell surface, it might be a useful marker in the diagnosis of advanced-stage cancer and a potential candidate for therapeutic intervention. 10, 27, 34 It is well known that sL1 is the extracellular domain of L1-CAM, which is shed from the cell surface by disintegrin ADAM10-and metalloprotease ADAM17-mediated cleavage. 12, 14, 35, 36 Several studies found sL1 released into the medium by breast, melanoma, colon, glioma, and ovarian cancer cell lines. 4, 11, [37] [38] [39] [40] Moreover, the release of sL1 was not restricted to carcinoma cells in culture but has recently been detected in serum and ascites fluid from patients with ovarian, endometrial, and lung cancer and patients with gastrointestinal stromal tumor (GIST). 11, 14, 15, 41 In our study, the serum 
Clinical Breast Cancer October 2018 -e859 sL1 levels in the patients with PBC were significantly greater than those in the patients with BBD or the HCs (P ¼ .021). We used ROC methods to evaluate the diagnostic value of the serum sL1 level (AUC, 0.61), which indicated that sL1 had a significant predictive value in PBC. Currently, the main peripheral blood tumor markers for BC are carcinoembryonic antigen and cancer antigen 15-3. The AUC for carcinoembryonic antigen and cancer antigen 15-3 levels in the blood from different BC and BBD cases was 0.754 and 0.637, respectively. 42 Previous studies from other research groups found elevated sL1 levels in the cell culture medium from 3 breast cancer cell lines, which promoted cancer cell adhesion to extracellular matrix and cell migration. 4 To the best of our knowledge, ours is the first report to explore elevated serum sL1 levels in patients with PBC. In our study, we observed that the significantly higher levels of sL1 in the serum of PBC patients correlated with larger tumor size, lymph node involvement, higher histologic grade, and more advanced TNM stage. Other studies also showed that sL1 levels correlated significantly with disease stage, progression, and recurrence in ovarian cancer and GIST patients. 41, 43, 44 It is not clear why higher sL1 levels predict for poor outcomes in BC and other types of cancer. Heiz et al 12 found that the release of sL1 from the renal carcinoma cell surface did not lead to L1-CAM downregulation but more likely served as a method to produce sL1. The generation of sL1 is not a mere byproduct of tumors. 11 Studies from other research groups have shown that sL1 can be detected at the invasive front of colon cancer, glioma, and breast cancer cell cultures, indicating that sL1 might play an important role in the initial stage of cancer cell migration. 4, 39, 45, 46 In BC, L1-CAM promotes progression by upregulating the expression and release of sL1, which then exerts its autocrine or paracrine stimulatory effect. 4, 47 We have confirmed that the sL1 levels are related to L1-CAM expression. Previous studies have shown that sL1 promotes BC cell adhesion and migration in vitro and stimulates cell migration. 4, 47 In cell culture, sL1 was identified through the interaction between tumor cells and vessel endothelial cells. 14, 48 These results indicate that the higher levels of sL1 might play a critical role in the advanced stages of tumor progression and the aggressive tumor invasiveness of BC. We also observed significantly higher levels of sL1 in the serum of the PBC patients with ERa À expression. ERa is an important factor in the epithelialemesenchymal transition (EMT) in BC. The EMT is a hallmark of aggressive tumors and has been implicated in the promotion of cancer cell invasion, metastasis, and drug resistance.
49
L1-CAM disrupts E-cadherinecontaining adherens junctions and increases the scattering and motility of MCF7 breast carcinoma cells. 45 The presence of L1-CAM in these cells also triggers a phenomenon reminiscent of EMT. 45 Overexpression of ERa suppresses the migration, invasion, and EMT of BC cells. 50 In contrast, the loss of ERa expression in breast cancer cells results in potent EMT. 51 Furthermore, we observed that patients with higher sL1 levels had significantly shorter DFS (P ¼ .011) compared with patients with lower sL1 levels. These observations are consistent with previous studies showing elevated sL1 as a negative prognostic marker for ovarian cancer and GIST and a trend toward decreasing OS, although the difference was not statistically significant (P ¼ .064).
41,44
Conclusion
Our study has indicated that the presence of L1-CAM and sL1 in PBC might correlate with poor clinical prognosis and reflect tumor progression and metastasis. Measurement of serum sL1 might provide useful information for screening and diagnosis and could be a prognostic indicator for poor outcomes in PBC. In addition, L1-CAM might be a potential target in the treatment of PBC.
Clinical Practice Points
The L1-CAM was originally discovered to be an important protein that plays a crucial role in axon guidance and cell migration in the nervous system. Recently, L1-CAM was found to be expressed in many malignant tumors, which correlated with unfavorable clinical outcomes. Its soluble form, sL1 is the extracellular domain of L1-CAM. Recent studies have shown that sL1 promotes cancer cell migration, invasion, and growth of human cancer cells; however, few studies have addressed L1-CAM expression and its association with clinicopathologic characteristics or the role of serum sL1 in the diagnosis of PBC. Furthermore, the association of sL1 with clinicopathologic characteristics remains unknown, and its effect on the prognosis of patients has not been investigated. In the present study, we investigatedL1-CAM expression in cancer and para-carcinoma tissues and the serum sL1 levels in 162 consecutive patients with PBC using immunohistochemistry and an enzyme-linked immunosorbent assay, respectively. Serum sL1 levels were also examined in 38 patients with BBD and 36 healthy controls. Our findings indicated that L1-CAM was expressed more frequently in cancer tissues and the mean sL1 levels were significantly greater in those with PBC. Thus, the presence of L1-CAM and sL1 in PBC might correlate with a poor clinical prognosis and reflect tumor progression and metastasis. Serum sL1 measurement might provide useful information for screening and diagnosis and might be a prognostic indicator for a poor outcome in PBC. In addition, L1-CAM might be a potential target for the treatment of PBC.
